Research ExplorerPublicationsPatient needs and benefits of sublingual immunotherapy for g...

Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study

Standard

Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study. / Klein, Toni Maria; Hadler, Meike; Augustin, Matthias; Blome, Christine.

In: IMMUNOTHERAPY-UK, Vol. 13, No. 14, 10.2021, p. 1193-1204.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Klein, TM, Hadler, M, Augustin, M & Blome, C 2021, 'Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study', IMMUNOTHERAPY-UK, vol. 13, no. 14, pp. 1193-1204. https://doi.org/10.2217/imt-2021-0161

APA

Klein, T. M., Hadler, M., Augustin, M., & Blome, C. (2021). Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study. IMMUNOTHERAPY-UK, 13(14), 1193-1204. https://doi.org/10.2217/imt-2021-0161

Vancouver

Klein TM, Hadler M, Augustin M, Blome C. Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study. IMMUNOTHERAPY-UK. 2021 Oct;13(14):1193-1204. https://doi.org/10.2217/imt-2021-0161

Bibtex

@article{aba89c46fa2b4f7abf1cb7c049529a78,
title = "Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study",
abstract = "Aim: Clinical efficacy of sublingual immunotherapy for grass pollen-induced allergic rhinitis (AR) needs to translate into patient benefit. Patients & methods: Patients received Oralair (Stallergenes, Antony, France) in real-life medical practice. Patient-relevant treatment benefits were measured with the AR-specific Patient Benefit Index. Subgroups were analyzed regarding distinct patient characteristics. Results: Data of 883 patients (children, adolescents, and adults) were analyzed. The highest-ranked patient needs referred to having less AR symptoms, being able to go outdoors, and being free in the choice of leisure activities. Most patients (89.2-94.6%) attained at least minimally relevant benefit. All subgroups reported relevant benefits, with significantly higher scores in some subgroups. Conclusion: Treatment with Oralair was associated with considerable patient-relevant benefit in all age groups.",
author = "Klein, {Toni Maria} and Meike Hadler and Matthias Augustin and Christine Blome",
year = "2021",
month = oct,
doi = "10.2217/imt-2021-0161",
language = "English",
volume = "13",
pages = "1193--1204",
journal = "IMMUNOTHERAPY-UK",
issn = "1750-743X",
publisher = "Future Medicine Ltd",
number = "14",

}

RIS

TY - JOUR

T1 - Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study

AU - Klein, Toni Maria

AU - Hadler, Meike

AU - Augustin, Matthias

AU - Blome, Christine

PY - 2021/10

Y1 - 2021/10

N2 - Aim: Clinical efficacy of sublingual immunotherapy for grass pollen-induced allergic rhinitis (AR) needs to translate into patient benefit. Patients & methods: Patients received Oralair (Stallergenes, Antony, France) in real-life medical practice. Patient-relevant treatment benefits were measured with the AR-specific Patient Benefit Index. Subgroups were analyzed regarding distinct patient characteristics. Results: Data of 883 patients (children, adolescents, and adults) were analyzed. The highest-ranked patient needs referred to having less AR symptoms, being able to go outdoors, and being free in the choice of leisure activities. Most patients (89.2-94.6%) attained at least minimally relevant benefit. All subgroups reported relevant benefits, with significantly higher scores in some subgroups. Conclusion: Treatment with Oralair was associated with considerable patient-relevant benefit in all age groups.

AB - Aim: Clinical efficacy of sublingual immunotherapy for grass pollen-induced allergic rhinitis (AR) needs to translate into patient benefit. Patients & methods: Patients received Oralair (Stallergenes, Antony, France) in real-life medical practice. Patient-relevant treatment benefits were measured with the AR-specific Patient Benefit Index. Subgroups were analyzed regarding distinct patient characteristics. Results: Data of 883 patients (children, adolescents, and adults) were analyzed. The highest-ranked patient needs referred to having less AR symptoms, being able to go outdoors, and being free in the choice of leisure activities. Most patients (89.2-94.6%) attained at least minimally relevant benefit. All subgroups reported relevant benefits, with significantly higher scores in some subgroups. Conclusion: Treatment with Oralair was associated with considerable patient-relevant benefit in all age groups.

U2 - 10.2217/imt-2021-0161

DO - 10.2217/imt-2021-0161

M3 - SCORING: Journal article

C2 - 34328018

VL - 13

SP - 1193

EP - 1204

JO - IMMUNOTHERAPY-UK

JF - IMMUNOTHERAPY-UK

SN - 1750-743X

IS - 14

ER -